Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Reportedly, Drugmaker Pfizer has informed that it has identified certain antiviral compounds in development that has the potential to inhibit coronaviruses. The company said it is yet to involve a third party to verify the compounds and expects to have the results from the screening by the end of March. If the compounds are successful, Pfizer expects to start testing them by the end of the year. Pfizer Chief Scientific Officer Mikael Dolsten met with U.S. President Trump at the White House on Monday as one of the pharmaceutical executives.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.